Determinants of buprenorphine treatment for opioid dependence

Published: October 25, 2013
Category: Bibliography > Papers
Authors: Dyck DG, Fishman PA, McPherson S, Murphy SM, Roll JR
Countries: United States
Language: null
Types: Population Health
Settings: Health Plan, PCP

J Subst Abuse Treat 46:315-319.

Washington State University, Spokane, WA, USA; Group Health Research Institute, Seattle, WA, USA

This study assessed the social, demographic and clinical determinants of whether an opioid-dependent patient received buprenorphine versus an alternative therapy. A retrospective cohort analysis of opioid-dependent adults enrolled in Group Health Cooperative between January 1, 2006 and December 1, 2010 was performed. Increasing the number of physicians with DATA waivers in a region and living in a relatively-populated area increased the likelihood of being treated with buprenorphine, indicating that lack of access is a potential barrier. Comorbidity also appeared to be a factor in receipt of treatment, with the effect varying by diagnosis. Finally, patients with an insurance plan allowing health services to be sought from any provider, with increased cost sharing, were significantly more likely to receive buprenorphine, implying that patient demand is a factor. Programs integrating patient education, physician training, and support from addiction specialists would be likely facilitators of increasing access to this cost-effective treatment.

PMID: 24209382

Medications,Co-morbidity,Practice Patterns Comparison,Cost Burden Evaluation,United States,Adult,Cohort Studies,Gender,Middle Aged,Retrospective Studies

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top